Oncology Business Management | Specialty

FDA Approves Olaparib for Advanced Ovarian Cancer

December 19th 2014

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

Clinical Pathways Can Lead to Cost Savings, Better Care

December 18th 2014

Several initiatives that have a dramatic impact on healthcare today were born during that time–managed care, transitioning away from inpatient care toward outpatient care, and the introduction of clinical pathways.

Final Thoughts on Improving Prostate Cancer Care

December 17th 2014

Integrating a Medical Oncologist Into Urology Practices

December 17th 2014

Combination Strategies Explored in CRPC

December 17th 2014

Integrating Radium-223 Into Clinical Practice

December 17th 2014

Providing Optimal Care for Prostate Cancer

December 17th 2014

Data: The New Currency in Healthcare Improvement

December 17th 2014

Integrating Dispensing Pharmacy Services Into a Urology Group

December 17th 2014

Multiparametric MRI Biopsies: Poised for Widespread Adoption?

December 17th 2014

Multiparametric MRI for Detecting Prostate Cancer

December 17th 2014

Large Groups Are Positioned Well in New Healthcare Arena

December 17th 2014

While Laszewski said the Affordable Care Act (ACA), which is driving many of the changes, may end up being altered, he doesn't expect the program to be disbanded due to the political shift in legislative power.

FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

December 16th 2014

The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Innovative Payment Models in Cancer Care

December 15th 2014

Faced with steep regulations, slashed reimbursement rates, and a shift in focus from fee-for-service (FFS) to delivering value, insurers and physician groups are experimenting with new forms of payment incentives.

FDA Approves Ramucirumab for NSCLC

December 12th 2014

The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

FDA Approves Blinatumomab for Acute Lymphoblastic Leukemia

December 3rd 2014

The FDA has approved the bispecific T cell engager antibody blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The Emerging "N-of-1" Model:Clinical Relevance of Individualized Tumor Profiling Grows in Research Programs

November 28th 2014

Molecular studies are increasingly utilized to develop an individual therapeutic approach based on abnormalities present in the setting of uncommon/rare cancers or in specific clinical situations where it is virtually certain that formal regulatory-based trials will never be undertaken.

Becoming a Champion of Change: Educating Fellows on the Costs of Cancer Care

November 27th 2014

On a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides

Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social Media

November 23rd 2014

It is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.